MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
MoonLake Immunotherapeutics reported positive Week 52 data from its Phase 3 VELA-1 and VELA-2 trials for sonelokimab in hidradenitis suppurativa (HS). 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100, with no new safety signals detected. The data supports a best-in-class profile, with superior efficacy compared to competitor agents and significant improvements in patient-reported outcomes like quality of life and pain. Interim data from the adolescent VELA-TEEN trial also showed strong response rates (~68% HiSCR75 at Week 24).
Key figures
- Drug Name
- sonelokimab
- Phase Of Trial
- Phase 3
- Hiscr75 week52
- 67.2%
- Hiscr100 week52
- 33.1%
- Ihs4 100 week52
- 26.0%
- Hisqol improvement
- -15.0 points
- Pain reduction pct
- 46.5%
- Bla submission date
- End of September 2026
- Pduefa date expectation
- End of November 2026
- Vela teen hisr75 week24
- ~68%
- Vela teen hisr100 week24
- ~45%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.